ArticleBMC cancer2026
Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to characterise the molecular effects of treating myelodysplastic syndrome (MDS) cells with the DNA methyltransferase inhibitor azacitidine and an PIM-2 inhibitor, focusing on their potential synergistic effects.
methodsMDS cells were subjected to proliferation assays to assess the effects of each drug independently and in combination. The synergy of the drugs in promoting the apoptosis of MDS cells via NF-κB signalling pathway inhibition was evaluated.
resultsOur results suggested that azacitidine and the PIM-2 inhibitor have synergistic effects in inhibiting the proliferation and inducing the apoptosis of MDS cells. Furthermore, the combined application of azacitidine and PIM-2 inhibitor synergistically inhibited the NF-κB pathway, resulting in the induction of apoptosis in MDS cells.
conclusionAdministration of a small molecule PIM-2 inhibitor in combination with the epigenetic drug azacitidine is one of the effective ways to treat MDS. Our study lays a foundation for future clinical trials in patients with MDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.